A Novel Multi-Model High Spatial Resolution Method for Analysis of DCE MRI Data: Insights from Vestibular Schwannoma Responses to Antiangiogenic Therapy in Type II Neurofibromatosis
Open Access
- 11 September 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1282
Abstract
This study aimed to develop and evaluate a new DCE-MRI processing technique that combines LEGATOS, a dual-temporal resolution DCE-MRI technique, with multi-kinetic models. This technique enables high spatial resolution interrogation of flow and permeability effects, which is currently challenging to achieve. Twelve patients with neurofibromatosis type II-related vestibular schwannoma (20 tumours) undergoing bevacizumab therapy were imaged at 1.5 T both before and at 90 days following treatment. Using the new technique, whole-brain, high spatial resolution images of the contrast transfer coefficient (Ktrans), vascular fraction (vp), extravascular extracellular fraction (ve), capillary plasma flow (Fp), and the capillary permeability-surface area product (PS) could be obtained, and their predictive value was examined. Of the five microvascular parameters derived using the new method, baseline PS exhibited the strongest correlation with the baseline tumour volume (p = 0.03). Baseline ve showed the strongest correlation with the change in tumour volume, particularly the percentage tumour volume change at 90 days after treatment (p < 0.001), and PS demonstrated a larger reduction at 90 days after treatment (p = 0.0001) when compared to Ktrans or Fp alone. Both the capillary permeability-surface area product (PS) and the extravascular extracellular fraction (ve) significantly differentiated the ‘responder’ and ‘non-responder’ tumour groups at 90 days (p < 0.05 and p < 0.001, respectively). These results highlight that this novel DCE-MRI analysis approach can be used to evaluate tumour microvascular changes during treatment and the need for future larger clinical studies investigating its role in predicting antiangiogenic therapy response.Keywords
Funding Information
- Cancer Research UK (CRUK) (C8742/A18097)
This publication has 66 references indexed in Scilit:
- Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applicationsNMR in Biomedicine, 2013
- Quantification of Perfusion and Permeability in Multiple SclerosisInvestigative Radiology, 2012
- MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current PracticeAmerican Journal of Neuroradiology, 2011
- Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related TumorsCancer Research, 2010
- Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2Neuro-Oncology, 2009
- Post-ischemic leakiness of the blood–brain barrier: A quantitative and systematic assessment by Patlak plotsExperimental Neurology, 2009
- Neurofibromatosis type 2 (NF2): A clinical and molecular reviewOrphanet Journal of Rare Diseases, 2009
- DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agentsBritish Journal of Cancer, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985